Global Leading Market Research Publisher QYResearch announces the release of its latest report "Oligonucleotide and Peptide Synthesis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". In modern biotechnology and pharmaceutical development, the ability to produce custom-designed nucleic acids and peptides at scale has become fundamental to therapeutic innovation. Researchers and drug developers face persistent challenges in achieving high-purity synthesis, scaling from research-grade to GMP-compliant production, and managing complex supply chains for novel therapeutic modalities. This report quantifies the market trajectory of oligonucleotide and peptide synthesis—cornerstone technologies enabling gene editing, antisense therapeutics, peptide-based drug discovery, and precision medicine applications.

The global market for Oligonucleotide and Peptide Synthesis was estimated to be worth US$ 1,085 million in 2025 and is projected to reach US$ 1,633 million, growing at a CAGR of 6.1% from 2026 to 2032.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097933/oligonucleotide-and-peptide-synthesis

Defining the Technology: Custom Biomolecule Manufacturing
Oligonucleotide and peptide synthesis represents a cornerstone technology in modern biotechnology and pharmaceutical industries, referring to the in vitro construction of nucleic acid fragments and peptide chains through chemical or enzymatic methods. Oligonucleotide synthesis, typically achieved by solid-phase synthesis, enables the production of custom-designed DNA or RNA sequences for applications in gene editing, molecular diagnostics, antisense therapeutics, RNA interference, and vaccine development. Peptide synthesis, often carried out via solid-phase peptide synthesis (SPPS) or liquid-phase methods, allows for the creation of tailored peptides used in drug discovery, protein structure-function studies, vaccine design, and advanced biomaterials. With the rise of precision medicine and nucleic acid-based therapeutics, oligonucleotide and peptide synthesis has evolved from a research tool into a critical driver of clinical translation and large-scale pharmaceutical manufacturing.

Market Segmentation: Oligonucleotide Synthesis vs. Peptide Synthesis
The market is segmented into oligonucleotide synthesis and peptide synthesis. Oligonucleotide synthesis represents the largest and fastest-growing segment, driven by the expansion of RNA-based therapeutics, including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and messenger RNA (mRNA) vaccines. The segment encompasses custom DNA and RNA synthesis across scales from research-grade to GMP-compliant commercial manufacturing, with increasing demand for chemically modified oligonucleotides featuring enhanced nuclease resistance and improved pharmacokinetic properties.

Peptide synthesis represents a stable, high-value segment serving therapeutic peptide development, peptide-based vaccines, and research applications. Solid-phase peptide synthesis (SPPS) dominates this segment, with increasing demand for long-chain peptides, cyclic peptides, and peptides incorporating non-natural amino acids. The segment has seen accelerated growth from the pipeline of peptide therapeutics addressing metabolic disorders, oncology, and infectious diseases.

Application Landscape: Biotech Companies and Academic Research Institutions
From an application perspective, the market serves two primary domains. Biotech companies represent the largest and fastest-growing segment, encompassing emerging oligonucleotide and peptide therapeutics developers and established pharmaceutical companies expanding into these modalities. This segment drives demand across the development lifecycle—from research-grade custom synthesis for early discovery through GMP-compliant manufacturing for clinical trials and commercial supply.

Academic scientific research institutions represent a stable segment, requiring custom oligonucleotide and peptide synthesis for basic research, translational studies, and early-stage proof-of-concept experiments. This segment prioritizes cost efficiency, rapid turnaround, and technical support for diverse applications.

Competitive Landscape: Global CDMOs and Specialized Synthesis Providers
The competitive landscape features established global CDMOs and specialized synthesis providers with deep technical expertise. Thermo Fisher Scientific, Merck, and Azenta Life Sciences dominate the premium segment, offering integrated solutions spanning synthesis, purification, analytical testing, and formulation across multiple global facilities.

TriLink BioTechnologies, Integrated DNA Technologies (IDT), and Eurogentec command significant share in modified oligonucleotide synthesis, leveraging proprietary chemistries. WuXi TIDES has emerged as a major player in the Asia-Pacific region, offering integrated oligonucleotide and peptide synthesis services. A robust Asian ecosystem includes Genscript, Cusabio, Macrogen, Synbio Technologies, and Guangzhou RiboBio capturing market share through cost-competitive services.

Industry Deep-Dive: Therapeutic Pipeline Expansion and Capacity Constraints
Over the past six months, the industry has witnessed accelerated demand driven by three converging factors. First, the oligonucleotide therapeutics pipeline has expanded dramatically, with over 80 oligonucleotide-based drugs in clinical development as of Q4 2025, spanning rare genetic disorders, cardiovascular disease, and oncology. The peptide therapeutics pipeline has similarly expanded, with over 150 peptide-based candidates in clinical development.

Second, the shift toward chemically modified oligonucleotides has increased technical requirements for synthesis platforms. A recent case study from a late-stage siRNA developer revealed that transitioning to commercial-scale GMP production required requalification of synthesis platforms, optimization of purification processes, and implementation of advanced analytical methods for impurity profiling—a process requiring substantial technical investment.

Third, regulatory expectations for synthetic biomolecule manufacturing have continued to evolve. The FDA's 2025 guidance on "Chemistry, Manufacturing, and Controls for Oligonucleotide and Peptide Therapeutics" emphasized the importance of demonstrating process control for impurity profiles, including failure sequences and process-related contaminants, driving increased investment in analytical capabilities among CDMOs.

Exclusive Insight: Divergence Between Oligonucleotide and Peptide Manufacturing
A distinct pattern emerges when comparing oligonucleotide and peptide synthesis markets. Oligonucleotide synthesis demonstrates a bimodal structure, with early-stage research dominated by rapid-turnaround custom synthesis providers and late-stage commercial manufacturing concentrated among specialized CDMOs with GMP-scale capacity. The transition from research to commercial scales requires requalification of synthesis platforms and substantial capital investment.

Peptide synthesis demonstrates a more fragmented structure, with many mid-sized CDMOs offering SPPS capabilities alongside large-scale manufacturers. The lower capital intensity for small-scale peptide synthesis has enabled broader participation, while the commercial segment remains concentrated among CDMOs with established regulatory track records and capacity for long-chain, complex peptides.

This divergence has strategic implications for synthesis providers. Oligonucleotide-focused providers must invest in commercial-scale capacity and advanced purification capabilities. Peptide-focused providers must differentiate through technical expertise in complex modifications and regulatory compliance.

Technical Barriers and Innovation Frontiers
For oligonucleotide synthesis, impurity control remains critical, with complex sequences generating diverse failure products requiring sophisticated analytical methods. Providers are implementing high-resolution mass spectrometry and ion-pair HPLC for comprehensive impurity profiling.

For peptide synthesis, challenges include aggregation during synthesis, racemization, and purification of long-chain peptides. Continuous manufacturing platforms offer potential for improved process control and throughput, with several providers piloting these technologies.

Future Outlook: Sustained Growth Through Therapeutic Pipeline Expansion
Looking toward 2032, the market is poised for sustained growth at a 6.1% CAGR, reaching US$1.6 billion. Key catalysts include continued expansion of oligonucleotide and peptide therapeutic pipelines, increasing adoption of chemically modified molecules with enhanced properties, and sustained outsourcing trends among emerging biotech developers. Providers delivering integrated solutions combining advanced synthesis platforms, robust purification capabilities, and demonstrated regulatory track records will capture disproportionate market share.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp